Abstract:Ubiquitination, an important type of protein posttranslational modification (PTM), plays a crucial role in controlling substrate degradation and subsequently mediates the "quantity" and "quality" of various proteins, serving to ensure cell homeostasis and guarantee life activities. The regulation of ubiquitination is multifaceted and works not only at the transcriptional and posttranslational levels (phosphorylation, acetylation, methylation, etc.) but also at the protein level (activators or repressors). When regulatory mechanisms are aberrant, the altered biological processes may subsequently induce serious human diseases, especially various types of cancer. In tumorigenesis, the altered biological processes involve tumor metabolism, the immunological tumor microenvironment (TME), cancer stem cell (CSC) stemness and so on. With regard to tumor metabolism, the ubiquitination of some key proteins such as RagA, mTOR, PTEN, AKT, c-Myc and P53 significantly regulates the activity of the mTORC1, AMPK and PTEN-AKT signaling pathways. In addition, ubiquitination in the TLR, RLR and STING-dependent signaling pathways also modulates the TME. Moreover, the ubiquitination of core stem cell regulator triplets (Nanog, Oct4 and Sox2) and members of the Wnt and Hippo-YAP signaling pathways participates in the maintenance of CSC stemness. Based on the altered components, including the proteasome, E3 ligases, E1, E2 and deubiquitinases (DUBs), many molecular targeted drugs have been developed to combat cancer. Among them, small molecule inhibitors targeting the proteasome, such as bortezomib, carfilzomib, oprozomib and ixazomib, have achieved tangible success. In addition, MLN7243 and MLN4924 (targeting the E1 enzyme), Leucettamol A and CC0651 (targeting the E2 enzyme), nutlin and MI-219 (targeting the E3 enzyme), and compounds G5 and F6 (targeting DUB activity) have also shown potential in preclinical cancer treatment. In this review, we summarize the latest progress in understanding the substrates for ubiquitination and their special functions in tumor metabolism regulation, TME modulation and CSC stemness maintenance. Moreover, potential therapeutic targets for cancer are reviewed, as are the therapeutic effects of targeted drugs.

Recent advances in the development of deubiquitinases inhibitors as antitumor agents

A review of deubiquitinases and thier roles in tumorigenesis and development

Ubiquitination and deubiquitination in cancer: from mechanisms to novel therapeutic approaches

Advances in deubiquitinating enzymes in lung adenocarcinoma

Roles and Mechanisms of Deubiquitinases (dubs) in Breast Cancer Progression and Targeted Drug Discovery

Emerging Role of DUBs in Tumor Metastasis and Apoptosis: Therapeutic Implication

The Emerging Role of Deubiquitinating Enzymes in Genomic Integrity, Diseases, and Therapeutics.

On the Study of Deubiquitinases: Using the Right Tools for the Job

Deubiquitinating Enzymes: Promising Targets for Drug Resistance.

Advances in the Development Ubiquitin-Specific Peptidase (USP) Inhibitors

The Roles of Deubiquitinating Enzymes in Cancer Therapy

Deubiquitylating Enzymes in Cancer and Immunity

Inhibition of Ubiquitin-Specific Proteases as a Novel Anticancer Therapeutic Strategy

Dysregulation of deubiquitination in breast cancer

Deubiquitinating enzymes: potential regulators of the tumor microenvironment and implications for immune evasion

Deubiquitinases in cancer

Targeting the Ubiquitin-Proteasome System and Recent Advances in Cancer Therapy

Progress in Anticancer Drug Development Targeting Ubiquitination-Related Factors

Post-Translational Modifications of Deubiquitinating Enzymes: Expanding the Ubiquitin Code

Function, mechanism and drug discovery of ubiquitin and ubiquitin-like modification with multiomics profiling for cancer therapy

The role of ubiquitination in tumorigenesis and targeted drug discovery